Showing 4,981 - 5,000 results of 5,016 for search '"Spain"', query time: 0.12s Refine Results
  1. 4981

    [Artículo traducido] Infecciones necrosantes de partes blandas: aproximación diagnóstico-terapéutica by A. Garrido-Hidalgo, J. García-Coiradas, M. Echevarría-Marín, S. Llanos, J.A. Valle-Cruz, F. Marco

    Published 2025-01-01
    “…This study analyzes the characteristics, demographics, complications, and treatment of NSTI in a hospital in Madrid, Spain. Methods: A retrospective observational study was conducted, including all surgically treated NSTI patients at our center from January 2016 to December 2022, examining epidemiological and clinical data. …”
    Get full text
    Article
  2. 4982
  3. 4983
  4. 4984
  5. 4985
  6. 4986
  7. 4987

    Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study by Patrice Cacoub, Arsène Mekinian, David Saadoun, Pavel I Novikov, Savino Sciascia, Corrado Campochiaro, Olivier Fain, Ilya Smitienko, Nicolas Schleinitz, Patrick Jégo, Francesco Muratore, Carlo Salvarani, Elena Galli, Sabine Berthier, Marc Lambert, François Maurier, Isabelle Kone-Paut, Sergey Moiseev, Masataka Kuwana, Alexandre Belot, Martin Michaud, Francis Gaches, Achille Aouba, Xavier Puechal, Karim Sacre, Tiphaine Goulenok, Alessandro Tomelleri, Thomas Sené, Elena Marina Baldissera, Luigi Boiardi, Abid Awisat, Ygal Benhamou, Vahan Mukuchyan, Mathieu Vautier, Azeddine Dellal, Lucie Biard, Julie Seguier, José Hernández-Rodríguez, Olivier Espitia, Sebastien Humbert, Guillaume Denis, Nolan Hassold, Dagna Lorenzo, Helene Munoz Pons, Jean Baptiste Gaultier, Le Mouel Edwige, Antoinette Perlat, Bertrand Lioger, Jonathan Broner, Virginie Dufrost, Faten Frikha, Alexandra Audemard-Verger, Pascal Woaye-Hune, Pierre Zeminsky, Moya Alvarado, Matheus Vieira, Alberto Lo Gullo

    Published 2023-06-01
    “…Objectives In this large multicentre study, we compared the effectiveness and safety of tocilizumab intravenous versus subcutaneous (SC) in 109 Takayasu arteritis (TAK) patients.Methods We conducted a retrospective multicentre study in referral centres from France, Italy, Spain, Armenia, Israel, Japan, Tunisia and Russia regarding biological-targeted therapies in TAK, since January 2017 to September 2019.Results A total of 109 TAK patients received at least 3 months tocilizumab therapy and were included in this study. …”
    Get full text
    Article
  8. 4988
  9. 4989

    The 0ν2β-decay CROSS experiment: preliminary results and prospects by The CROSS collaboration, I. C. Bandac, A. S. Barabash, L. Bergé, M. Brière, C. Bourgeois, P. Carniti, M. Chapellier, M. de Combarieu, I. Dafinei, F. A. Danevich, N. Dosme, D. Doullet, L. Dumoulin, F. Ferri, A. Giuliani, C. Gotti, P. Gras, E. Guerard, A. Ianni, H. Khalife, S. I. Konovalov, E. Legay, P. Loaiza, P. de Marcillac, S. Marnieros, C. A. Marrache-Kikuchi, C. Nones, V. Novati, E. Olivieri, C. Oriol, G. Pessina, D. V. Poda, T. Redon, V. I. Tretyak, V. I. Umatov, M. M. Zarytsky, A. S. Zolotarova

    Published 2020-01-01
    “…The present program envisions an intermediate experiment to be installed underground in the Canfranc laboratory (Spain) in a CROSS-dedicated facility. This experiment, comprising ∼ 3×1025 nuclei of 100Mo, will be a general test of the CROSS technology as well as a worldwide competitive search for neutrinoless double-beta decay, with sensitivity to the effective Majorana mass down to 70 meV in the most favorable conditions.…”
    Get full text
    Article
  10. 4990
  11. 4991
  12. 4992

    Le nivellement des aqueducs de Lyon et leurs aménagements de régulation et de ralentissement : analyse et mise en perspective by Laetitia Borau

    Published 2023-12-01
    “…These hydraulic staircases can be compared to those of Autun, Cordoba (Spain), Cherchell and Rusicade (Algeria).It is still difficult to assess the reasons that led the builders to favour one or another slowing system, chutes or dropshafts. …”
    Get full text
    Article
  13. 4993
  14. 4994
  15. 4995
  16. 4996
  17. 4997
  18. 4998
  19. 4999
  20. 5000